Clinical Manifestations of Persistent Smear Positive and Culture Negative Sputum Tests 5 Months after First-Line Anti-Tuberculous Chemotherapy

일차 항결핵제 치료 5개월 후 도말 양성 및 배양 음성을 보이는 폐결핵 환자의 임상 양상

  • Received : 2007.10.25
  • Accepted : 2007.11.14
  • Published : 2007.11.30

Abstract

Background: It is not known with certainty whether patients with persistently positive sputum smear results who have also had negative sputum culture results require prolongation of treatment for tuberculosis in order to avoid an increased risk of eventual relapse. The purpose of the present study was to retrospectively describe the treatment characteristics and evaluate the appropriate duration of treatment in these patients. Methods: Sixty of 69 patients with sputum smear positive and culture negative tests at 5 months after first line anti-tuberculous chemotherapy from 2002 to 2003 were retrospectively analyzed. Exclusion criteria included incomplete treatment or resistance to rifampicin or two additional antibiotics, as determined by a drug susceptibility test (DST). Results: Smear conversion of the study subjects was observed after $8.3{\pm}2.3$ months treatment, and the patients were culture negative after $2.0{\pm}0.8$ months. The relapse rates of the study subjects were 3.8, 10.0, and 25.8% after 1, 2, and 5 years of anti-tuberculosis chemotherapy, respectively. The relapse rates were not significantly affected by a series of risk factors such as age, sex, presence of diabetes, a sputum culture examination after 2 months treatment, previous treatment history, chest radiograph, and duration of the treatment (P>0.05). Conclusion: Regimen change is not required for patients with persistent smear positive but culture negative tests in the fifth month for first line antituberculous treatment. However, a further study will be needed to clarify the high relapse rate in this specific group of patients.

연구배경: 일차 항결핵제 치료 5개월 이후 배양 음전되었으나 도말 양성을 보이는 폐결핵 환자들의 임상적 특성과 치료 후 경과에 대하여 알아보고자 하였다. 방 법: 2002년 1월 1일부터 2003년 12월 31일까지 일개 결핵 전문 병원에 입원한 환자 중 일차 항결핵제로 치료를 종결하였고 약제감수성 검사상 일차 항결핵제에 모두 감성이거나 리팜핀을 제외한 단일 약제 내성이면서 추적관찰이 되었던 환자를 대상으로 임상적 특성과 재발여부와 이에 관련한 위험인자를 후향적으로 분석하였다. 결 과: 대상 환자는 60명이었고 모두 치료에 성공하였다. 객담 도말 검사상 음전은 평균 $8.3{\pm}2.3$개월이었고, 객담 배양 검사상 음전은 평균 $2.0{\pm}0.8$개월이었다. 당뇨는 14명(23%), 초치료는 46명(77%), 약제감수성 검사상 일차 항결핵제에 모두 감성인 경우가 37명(62%), 흉부방사선사진상 중증인 경우가 49명(81%)이었다. 재발률은 치료 1년 후 3.8%, 2년 후 10%, 5년 후 25.8%이었고 나이, 성별, 당뇨, 치료 2개월째의 배양검사 결과, 과거 치료력, 흉부방사선 사진 소견, 치료기간에 따라 재발률의 차이는 통계적으로 유의하지 않았다. 결 론: 일차 항결핵제로 치료시작 후 5개월에 객담 배양검사는 음전되었으나 도말검사는 양성인 환자들에서 치료약제의 변경 없이 모든 환자에서 치료가 성공되었다. 그러나 높은 재발률에 대한 추가적인 연구가 필요할 것으로 사료된다.

Keywords

References

  1. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. Br J Dis Chest 1981;75:141-53 https://doi.org/10.1016/0007-0971(81)90046-2
  2. Korea Center for Disease Control & Prevention. 2007 Tuberculosis. Seoul:Korea Center for Disease Control & Prevention;2007
  3. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129: 264-8
  4. Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999;116:726–31
  5. Vidal R, Martin-Casabona N, Juan A, Falgueras T, Miravitlles M. Incidence and significance of acid fast bacilli in sputum smears at the end of antituberculous treatment. Chest 1996;109:1562-5 https://doi.org/10.1378/chest.109.6.1562
  6. Sundaram V, Fujiwara PI, Driver CR, Osahan SS, Munsiff SS. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion. Int J Tuberc Lung Dis 2002;6:238-45
  7. National Tuberculosis Association of the USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961
  8. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998;12:505-10 https://doi.org/10.1183/09031936.98.12020505
  9. Guler M, Unsal E, Dursun B, Aydln O, Capan N. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007;61:231-5 https://doi.org/10.1111/j.1742-1241.2006.01131.x
  10. Chang SC, Yoon YM, Hong YP. Relapse rates within one year after the completion of treatment with short course chemotherapy for pulmonary tuberculosis under programme conditions. Tuberc Respir Dis 1987;34: 137-43
  11. Frieden T. Toman's Tuberculosis: case detection, treatment, and monitoring - questions and answers. 2nd ed. Geneva: World Health Organization; 2004
  12. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007;11: 828-37
  13. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430-5. https://doi.org/10.1164/rccm.200409-1200OC
  14. Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002; 6:3-10
  15. Ormerod LP, Horsfield N, Green RM. Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? J Infect 2001;42:1-3 https://doi.org/10.1053/jinf.2000.0773
  16. Koh WJ, Kwon OJ, Yu CM, Jeon K, Kim KC, Lee BH, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis 2004;56:248-60 https://doi.org/10.4046/trd.2004.56.3.248
  17. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-62 https://doi.org/10.1164/rccm.167.4.603